Chapter 11

Novel Patents and Cancer Therapies for Transforming Growth Factor-β and Urokinase Type Plasminogen Activator: Potential Use of Their Interplay in Tumorigenesis

Jelena Krstić, Irina Maslovarić, Hristina Obradović, Tamara Kukolj and Juan F. Santibanez


Transforming growth factor beta1 (TGF-β1) plays different roles in health and disease. TGF-β1 has been assumed as a dual factor in tumor growth, since it can repress epithelial tumor development in early stages, while it acts as a tumor promoter in the late stages of tumor progression. Cancer cells, during carcinogenesis, acquire migration and invasion capacity which enables them to metastasize. The urokinase type plasminogen activator (uPA) system, comprised of uPA, the cell surface receptor (uPAR) and plasminogen-plasmin, is involved in the proteolytic degradation of the extracellular matrix and it also regulates several critical cellular events by its capacity to trigger the activation of intracellular signaling pathways. This enables the cancer cell survival, its dissemination, and enhancement of cell malignancy during tumor progression. The expression of both uPA and uPAR is finely regulated in normal development, but their expression is deregulated in cancer. TGF-β regulates uPA expression in cancer cells while uPA, by conversion of plasminogen to active form, plasmin, may release TGF-β1 from its latent state. Thus, these pathways cross-regulate each other by mutual feedback contributing to tumor progression. Here, we review the specific roles and the interplay between TGF-β1 and uPA system in cancer cells, the current cancer therapies and the novel patents focused mainly on uPA and TGF-β ligands and their cell surface receptors. Finally, with regard to the mutual activity of uPA and TGF-β1 in tumorigenesis, the aim of this chapter is to expose the potential of TGF-β1 and uPA systems to become combinatorial targets for therapies and patents.

Total Pages: 660-716 (57)

Purchase Chapter  Book Details


.Topics in Anti-Cancer Research.
.Frontiers in Clinical Drug Research - Anti-Cancer Agents.
.The Evolution of Radionanotargeting towards Clinical Precision Oncology: A Festschrift in Honor of Kalevi Kairemo.
.Modern Cancer Therapies and Traditional Medicine: An Integrative Approach to Combat Cancers.